Subcutaneous ketorolac- a new development in pain control

Blackwell, N.; Bangham, L.; Hughes, Michelle M.; Melzack, D.; Trotman, I F

doi:10.1177/026921639300700110

Cited by 33 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combined patient population of case reports (5) and observational studies (2) was small (91 patients) and included diverse pain syndromes related to cancer, including bone and neuropathic pain. [6][7][8][9][10][11][12] The dose and delivery method and outcome measurements were different among the studies, making data synthesis somewhat challenging. Length of therapy was extended (>5 days) in a majority of the patients and was associated with 6 GI bleeding events, but no renal adverse events were reported.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Subcutaneous Ketorolac for Pain Management

2015

View full text Add to dashboard Cite

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Myers and Trotman 12 expanded the findings of Blackwell et al 6 and reported the single-center observations of 36 inpatients with advanced malignant disease-associated pain treated with ketorolac CSI. All patients were receiving oral opioids.…”

Section: Observational Studiesmentioning

confidence: 91%

The Role of Subcutaneous Ketorolac for Pain Management

2015

View full text Add to dashboard Cite

show abstract

“…It should be mentioned that when appropriate, ketorolac offers the advantage of parenteral administration (including subcutaneous) and thus is considered unique. This obviously does not affect concerns over the integrity of gastric mucosa [5].…”

Section: Nonopioid Analgesicsmentioning

confidence: 99%

Opioid and nonopioid therapy in cancer pain: The traditional and the new

Zekry

Reddy

1999

Current Review of Pain

View full text Add to dashboard Cite

Management of cancer pain has made sidnificant progress in recent years, partly due to the Agency for Health Care Policy and Research (AHCPR) guidelines, but mostly it seems to be due to the death and dying movement in the world. However, cancer pain on occasion poses significant problems and needs accurate diganosis and appropriate intervention. Pharmacotherapy remains the mainstay of treating cancer pain. Most cancer pain syndromes present with moderate to severe pain, associated with several comorbid problems necessitating the multidisciplinary approach to optimally treat it. The psychologic factors associated wth serious illness, terminal prognoses, and dying complicate the scenario even more as compared with that of nonmalignant pain. Although such patients are entitled to more aggressive analgesic therapy, it is unfortunate that this is not achieved in a significant percentage of cases. In this review, we address some of the above issues and attempt to summarize the traditional pharmacologic therapies highlighting their modern modes of implementation in cancer pain management. Special emphasis on the state-of-the art innovations in this field wil be noted.

show abstract

“…Several studies have shown an opioid sparing effect in cases of postoperative pain 17,18 and there are anecdotal reports of its successful use in cancer related pain,19 including some cases of neuropathic pain. The side effect profile seems similar to that of other non-steroidal anti-inflammatory drugs.…”

Section: Non-steroidal Anti-inflammatory Drugsmentioning

confidence: 99%

Current Issues in Cancer Palliative care

Davis

Hardy

1994

BMJ

View full text Add to dashboard Cite

Though many of the treatment strategies used in palliative care have never been subjected to clinical trial, it has been argued that advances in palliative care have outstripped those in many other specialties. This article is not a comprehensive review of therapeutic options, nor even of recent advances in this topic, but concentrates on the latest developments and controversies in the pharmacological treatment of four frequent and important symptoms: neuropathic pain, anorexia and cachexia, intestinal obstruction, and breathlessness. It is difficult to perform blinded, randomised trials in patients with advanced disease and poor performance status, yet it is these patients who may gain most from the adoption of new well evaluated treatment strategies.

show abstract

Subcutaneous ketorolac- a new development in pain control

Cited by 33 publications

References 5 publications

The Role of Subcutaneous Ketorolac for Pain Management

The Role of Subcutaneous Ketorolac for Pain Management

Opioid and nonopioid therapy in cancer pain: The traditional and the new

Current Issues in Cancer Palliative care

Contact Info

Product

Resources

About